Literature DB >> 15009533

Biological and conformational study of beta-substituted prolines in MT-II template: steric effects leading to human MC5 receptor selectivity.

M Cai1, C Cai, A V Mayorov, C Xiong, C M Cabello, V A Soloshonok, J R Swift, D Trivedi, V J Hruby.   

Abstract

To investigate the molecular basis for the interaction of the chi-constrained conformation of melanotropin peptide with the human melanocortin receptors, a series of beta-substituted proline analogs were synthesized and incorporated into the Ac-Nle-C[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 (MT-II) template at the His6 and D-Phe7 positions. It was found that the binding affinities generally diminished as the steric bulk of the p-substituents of the 3-phenylproline residues increased. From (2S, 3R)-3-phenyl-Pro6 to (2S, 3R)-3-(p-methoxyphenyl)-Pro6 analogs the binding affinity decreased 23-fold at the human melanocortin-3 receptor (hMC3R), 17-fold at the hMC4R, and eight-fold at the hMC5R, but selectivity for the hMC5R increased. In addition, the substitution of the D-Phe7 residue with a (2R, 3S)-3-phenyl-Pro resulted in greatly reduced binding affinity (10(3)-10(5)) at these melanocortin receptors. Macromodel's Large Scale Low Mode (LLMOD) with OPLS-AA force field simulations revealed that both MT-II and SHU-9119 share a similar backbone conformation and topography with the exception of the orientation of the side chains of D-Phe7/D-Nal (2')7 in chi space. Introduction of the dihedrally constrained phenylproline analogs into the His6 position (analogs 2-6) caused topographical changes that might be responsible for the lower binding affinities. Our findings indicate that hMC3 and hMC4 receptors are more sensitive to steric effects and conformational constraints than the hMC5 receptor. This is the first example for melanocortin receptor selectivity where the propensity of steric interactions in chi space of beta-modified Pro6 analogs of MT-II has been shown to play a critical role for binding as well as bioefficacy of melanotropins at hMC3 and hMC4 receptors, but not at the hMC5 receptor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15009533     DOI: 10.1111/j.1399-3011.2003.00105.x

Source DB:  PubMed          Journal:  J Pept Res        ISSN: 1397-002X


  31 in total

1.  Interactions of human melanocortin 4 receptor with nonpeptide and peptide agonists.

Authors:  Irina D Pogozheva; Biao-Xin Chai; Andrei L Lomize; Tung M Fong; David H Weinberg; Ravi P Nargund; Michael W Mulholland; Ira Gantz; Henry I Mosberg
Journal:  Biochemistry       Date:  2005-08-30       Impact factor: 3.162

2.  Effects of macrocycle size and rigidity on melanocortin receptor-1 and -5 selectivity in cyclic lactam alpha-melanocyte-stimulating hormone analogs.

Authors:  Alexander V Mayorov; So-Yeop Han; Minying Cai; Matthew R Hammer; Dev Trivedi; Victor J Hruby
Journal:  Chem Biol Drug Des       Date:  2006-05       Impact factor: 2.817

3.  Design, synthesis, and biological evaluation of a new class of small molecule peptide mimetics targeting the melanocortin receptors.

Authors:  James P Cain; Alexander V Mayorov; Minying Cai; Hui Wang; Bahar Tan; Kevin Chandler; YeonSun Lee; Ravil R Petrov; Dev Trivedi; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2006-08-22       Impact factor: 2.823

4.  Cell signaling and trafficking of human melanocortin receptors in real time using two-photon fluorescence and confocal laser microscopy: differentiation of agonists and antagonists.

Authors:  Minying Cai; Eva V Varga; Magda Stankova; Alexander Mayorov; Joseph W Perry; Henry I Yamamura; Dev Trivedi; Victor J Hruby
Journal:  Chem Biol Drug Des       Date:  2006-10       Impact factor: 2.817

5.  Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities.

Authors:  Alexander V Mayorov; Minying Cai; Kevin B Chandler; Ravil R Petrov; April R Van Scoy; Zerui Yu; Dustin K Tanaka; Dev Trivedi; Victor J Hruby
Journal:  J Med Chem       Date:  2006-03-23       Impact factor: 7.446

Review 6.  Melanotropins as drugs for the treatment of obesity and other feeding disorders: potential and problems.

Authors:  Minying Cai; Joel Nyberg; Victor J Hruby
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

7.  Structure-activity studies of new melanocortin peptides containing an aromatic amino acid at the N-terminal position.

Authors:  Paolo Grieco; Minying Cai; Alexander V Mayorov; Dev Trivedi; Victor J Hruby
Journal:  Peptides       Date:  2005-11-21       Impact factor: 3.750

8.  Utilize conjugated melanotropins for the earlier diagnosis and treatment of melanoma.

Authors:  Minying Cai; Zhonglin Liu; Hongchang Qu; Helen Fan; Zhiping Zheng; Victor J Hruby
Journal:  Eur J Pharmacol       Date:  2011-02-16       Impact factor: 4.432

Review 9.  Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles.

Authors:  Victor J Hruby; Minying Cai
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013       Impact factor: 13.820

10.  An unusual conformation of γ-melanocyte-stimulating hormone analogues leads to a selective human melanocortin 1 receptor antagonist for targeting melanoma cells.

Authors:  Minying Cai; Magda Stankova; Dhanasekaran Muthu; Alexander Mayorov; Zhehui Yang; Devendra Trivedi; Christopher Cabello; Victor J Hruby
Journal:  Biochemistry       Date:  2013-01-15       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.